Hot Flashes - Market Insights, Epidemiology and Market Forecast-2027

DelveInsight Business Research LLP


Albany, NY -- (SBWIRE) -- 09/24/2018 -- DelveInsight has announced the addition of the  "Hot Flashes - Market Insights, Epidemiologyand Market Forecast-2027'" drug pipelines to their offering.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Hot Flashes from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Hot flashes (HF) are often described as episodic sensations of heat, intense sweating, and flushing affecting the face and chest, which are often accompanied by palpitations and anxiety. Each particular episode lasts 3–10 minutes and episodes can recur with varying frequency. Some women experience hot flashes hourly or daily, whereas for others they may occur occasionally. The age at onset of hot flashes also varies from woman to woman. Hot flashes typically begin as the sudden sensation of heat centered on the upper chest and face. When moderate or severe, the hot flash rapidly become generalized, lasts from 2 to 4 minutes, and can
be associated with profuse perspiration, palpitations, or anxiety.

The Hot Flashes epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented by Total Prevalent Population of Hot Flashes Associated with Post-menopause and Severity-Specific Prevalent Population of Hot Flashes Associated with Post-menopause] scenario of Hot Flashes in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to DelveInsight, prevalent population of Hot Flashes associated with menopause in 7MM countries is expected to increase at a CAGR of 0.208% for the study period i.e. 2016-2027.
As per the estimates, United States has the highest prevalent population of Hot Flashes associated with Post Menopause. Among the European countries, Germany had the highest prevalent population of Hot Flashes with 5,215,367 cases, followed by France, which had prevalent population of 3,485,768 in 2016.

Geography Covered

? The United States
? EU5 (Germany, France, Italy, Spain and the United Kingdom)
? Japan

Study Period: 2016-2027

Hot Flashes Drug Companies

1. TherapeuticsMD
2. Besins Healthcare
3. Mithra Pharmaceuticals
4. Pherin Pharmaceuticals
5. Ogeda/Astellas
6. Nerre Therapeutics
And many others

Drugs covered

1. TX-001HR
2. BHR-401
3. Donesta
4. Salubrin
5. Fezolinetant
6. NT-814
And many others

Request for Sample Pages : Click here

Report Scope

1. The report covers detailed overview of Hot Flashes explaining its causes, symptoms,
classification, pathophysiology, diagnosis and treatment patterns
2. The report provides the insight about the historical and forecasted patient pool of Hot
Flashes in 7 major markets covering the United States, EU5 (Germany, Spain, France,
Italy, UK) & Japan
3. The Report assesses the disease risk and burden and highlights the unmet needs of
the disease
4. The Report helps to recognize the growth opportunities in the 7MM with respect to
the patient population